QR-Code

Exploring Predictive Factors for Bulevirtide Treatment Response in Hepatitis Delta-Positive Patients

<b>Background:</b> Hepatitis delta virus (HDV) infection represents the most severe form of viral hepatitis and is a significant global health challenge. Bulevirtide (BLV) is a novel therapeutic treatment that has resulted in variable response rates in HBV/HDV-coinfected patients. We evaluated clini...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Verdiana Zulian, Leonidas Salichos, Chiara Taibi, Silvia Pauciullo, Levi Dong, Gianpiero D’Offizi, Elisa Biliotti, Alessia Rianda, Luigi Federici, Angela Bibbò, Martina De Sanctis, Fiona McPhee, Anna Rosa Garbuglia
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI AG 2025-01-01
Schriftenreihe:Biomedicines
Schlagworte:
HDV
bulevirtide
antiviral treatment
Anti-HBc IgG
genetic variability
Online-Zugang:https://www.mdpi.com/2227-9059/13/2/280
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge